---

Systemic review of safety and efficacy of approved bio similar for management of rheumatoid arthritis

Full Text PDF

---

Review Article

Author Details : Dheeraj Rastogi*, Partha P Das, Manish Khanna

Volume : 10, Issue : 1, Year : 2024

Article Page : 1-8

https://doi.org/10.18231/j.ijos.2024.001

Suggest article by email

Get Permission

Abstract

Biological medicines have opened up new doors to treat many diseases, which include cancers, autoimmune conditions, diabetes, and so on. Stem-cell and gene therapies, insulin, and monoclonal antibodies are all some of the many instances of biological therapies.Biological Disease-modifying antirheumatic drugs (bDMARDs), such as monoclonal antibodies and receptor Fc-fusion proteins that target the tumor necrosis factor (TNF), are the recent development in treatment for patients with rheumatic conditions. Patients who are inadequate respondents to stand-alone conventional synthetic DMARDs have significant improvement in symptoms and outcomes with bDMARDs in various rheumatic conditions. Despite the betterment of the disease, the higher cost when compared to the conventional DMARDs makes bDMARDs less accessible to underprivileged patients. This inequality in the treatment because of the increased cost is being bridged nowadays with the development of lower-cost agents. This review evaluates the safety and efficacy of the Biosimilars in the treatment of Rheumatoid arthritis.
 

Keywords: Disease­modifying antirheumatic drugs (dmards), Rheumatoid arthritis therapy, Rheumatoid arthriitis, Biosimilars in RA, Biosimilars.

How to cite : Rastogi D, Das P P, Khanna M, Systemic review of safety and efficacy of approved bio similar for management of rheumatoid arthritis. Indian J Orthop Surg 2024;10(1):1-8

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.